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Heart-Type Fatty Acid-Binding
Protein Predicts Long-Term Mortality
After Acute Coronary Syndrome and Identifies
High-Risk Patients Across the Range of Troponin Values
Niamh Kilcullen, MRCPI,* Karthik Viswanathan, MRCP,* Rajiv Das, MRCP,* Christine Morrell,*
Amanda Farrin, MSC,† Julian H. Barth, MD, FRCP, FRCPATH,‡ Alistair S. Hall, PHD, FRCP,*
for the EMMACE-2 Investigators
Leeds, United Kingdom
Objectives Our aim was to determine if a high-performance assay for heart-type fatty acid-binding protein (H-FABP) has a
role in predicting all-cause mortality after acute coronary syndrome (ACS).
Background Heart-type fatty acid-binding protein is released into the circulation following myocardial ischemia and necrosis
and therefore may be of value to physicians when caring for patients admitted to hospital with a clinical diagno-
sis of ACS.
Methods This was a prospective observational study with a follow-up of 12 months. The H-FABP was measured 12 to 24 h
after onset of symptoms in 1,448 patients admitted to hospital with ACS. The main outcome measure was all-
cause mortality 1 year after index hospital admission. Multivariable analyses were conducted using the well vali-
dated GRACE (Global Registry of Acute Coronary Events) variables together with troponin I and highly sensitive
C-reactive protein (hs-CRP).
Results After 12 months of follow-up, 296 patients had died. Multivariable analysis demonstrated that H-FABP quartiles
were strongly predictive of outcome: Q1 hazard ratio (HR) 1.0; Q2 HR 2.32 (95% confidence interval [CI] 1.25 to
4.30; p  0.007); Q3 HR 3.17 (95% CI 1.73 to 5.82; p  0.001); Q4 HR 4.88 (95% CI 2.67 to 8.93; p  0.001).
The crude all-cause 1-year mortality for unstable angina patients with H-FABP 5.8 g/l was 2.1% compared
with 22.9% for patients above this cutoff. The adjusted all-cause mortality HR in this group was 11.35 (95% CI
2.00 to 64.34; p  0.006).
Conclusions Heart-type fatty acid-binding protein predicts long-term mortality after ACS and identifies high-risk patients in a
manner that is additive to the GRACE clinical risk factors, troponin, and hs-CRP, possibly as a result of identify-
ing the occurrence of myocardial ischemia with or without necrosis. (J Am Coll Cardiol 2007;50:2061–7)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.021m
m
r
m
s
t
p
q
H
ieart-type fatty acid-binding protein (H-FABP) is a
ow-molecular-weight protein involved in the intracellu-
ar uptake and buffering of free fatty acids in the
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ccepted August 21, 2007.yocardium (1). It was first noted to be a marker of
yocardial infarction (MI) in 1988 (2). Because it is
apidly released from the cytosol into the circulation after
yocardial ischemia and necrosis (3), H-FABP has been
hown to be a sensitive early marker of MI (4,5). Despite
his fact, initial studies performed using nonspecific
See page 2068
olyclonal antibody assays were disappointing. Conse-
uently, there has been relatively little attention given to
-FABP as an early marker of myocardial necrosis/
schemia. However, O’Donoghue et al. (6) have recently
eported on the prognostic value of H-FABP in a subset
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H-FABP Predicts Mortality in Acute Coronary Syndrome November 20, 2007:2061–7of 2,287 participants (22%) of
the TIMI (Thrombolysis In
Myocardial Infarction)-16 trial
demonstrating a clear associa-
tion with a composite end point
of death, MI, or heart failure at
10 months. This was present in
all subsets of patients (i.e.,
based on age, gender, renal
function, and so on) (6). We
report on the clinical performance
of a sensitive H-FABP assay to
further clarify its role in predict-
ing adverse prognosis after acute
coronary syndrome (ACS) when
sed in combination with a routine measurement (12 to
4 h after onset of symptoms) of cardiac troponin.
ethods
atient recruitment. Over a 6-month period (April 28,
003 to October 28, 2003) the EMMACE (Evaluation of
ethods and Management of Acute Coronary Events)-2
tudy identified and validated 2,499 consecutive consenting
atients with ACS from 11 adjacent hospitals in West
orkshire, United Kingdom (7). Of these, 1,448 had
ufficient blood sample remaining after routine local analy-
es for the measurement of H-FABP and troponin I (TnI)
entrally. Patients were potentially eligible if they were
dmitted to hospital either through the emergency depart-
ent or directly to the ward with an admission diagnosis of
uspected ACS. The judgement regarding appropriateness
f inclusion was made by a specialist cardiology research
urse in conjunction with a cardiology research registrar,
aking into account the views and opinions of the attending
edical team. This was based first on the clinical context
nd second on the results of cardiac biomarkers. Specifically,
atients were included in the study if they fulfilled a
evised European Society of Cardiology/American Col-
ege of Cardiology definition (8) of myocardial infarction:
aised troponin value above the 10% coefficient of varia-
ion (CV) taken 12 to 24 h after the onset of symptoms
ccompanied by at least 1 of the following: 1) ischemic
ymptoms; 2) development of pathologic Q waves on the
lectrocardiogram (ECG); 3) ECG changes indicative of
schemia; 4) delivery of primary coronary angioplasty; and
) compatible postmortem findings. We also included
ome unstable angina patients who were TnI negative
measured centrally) on the basis of clinical and ECG
iagnosis. In these patients, symptoms were sufficient to
arrant acute admission to hospital and diagnosis was
ased on an appropriate clinical history (chest pain
elieved to be indicative of myocardial ischemic origin),
CG findings (ST-segment depression, T-wave changes,
undle branch block, other abnormalities), and the results
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CV  coefficient of
variation
ECG  electrocardiogram
H-FABP  heart-type fatty
acid-binding protein
hs-CRP  highly sensitive
C-reactive protein
MI  myocardial infarction
TnI  troponin If locally used troponin assays. Patients may also have ween considered to be troponin positive on a local assay
ut later reclassified as negative based on central mea-
urement using the Beckman Coulter Accu TnI assay
High Wycombe, Buckinghamshire, United Kingdom).
atients were excluded if they refused consent or if they
ere judged not to have a diagnosis of ACS. Our intention
as to include a wide range of consenting ACS patients into
he study. The study was approved by the Multi Research
thics Committee and the Local Research Ethics Commit-
ees for each of the participating hospitals. All patients were
ollowed up long term for survival which was tracked
hrough the Office of National Statistics (ONS).
lood sampling and assays. The serum or plasma sample
btained from patients 12 to 24 h after the onset of
ymptoms, taken for routine diagnostic purposes, was saved
or later measurement of TnI and H-FABP. Of the 1,448
amples analyzed, there were 1,180 (82%) serum and 268
18%) plasma samples. Previous work showed that
-FABP concentrations were 13% higher in serum samples
ompared with plasma (N. Kilcullen, unpublished data,
004). Serum samples were also obtained from 96 (48 male,
8 female) healthy controls to assess the reference limits for
-FABP in our laboratory. The mean age of controls was
5 years (SD 9.5 years; median age 44 years; range 27 to 69
ears). All samples were centrifuged and frozen at 70°C
ithin 6 h of venipuncture. Sample stability tests showed
o significant change in H-FABP concentrations after 12
onths’ storage (N. Kilcullen, unpublished data, 2004).
he H-FABP was measured using a 2-step direct sand-
ich enzyme-linked immunosorbent assay using 2 dis-
inct mouse antihuman H-FABP monoclonal antibodies
Dainippon Pharmaceutical Co., Osaka, Japan). A cutoff
alue of 5.8 g/l was used to define abnormality based on
he 99th percentile for the 96 healthy controls. The
ntra-assay CV for H-FABP was 3.4% at 6 g/l and 6.9%
t 12 g/l. The interassay CV for H-FABP was 6.3% at
g/l and 8.3% at 12 g/l. The mean minimum
etectable concentration of H-FABP is 1.25 g/l (man-
facturer’s data). Patients with H-FABP concentrations
5.8 g/l were subsequently defined as being H-
ABP—and those with values of 5.8 g/l were defined
s being H-FABP.
Patients were included in the EMMACE-2 cohort based
redominantly, though not exclusively, on initial troponin
easurements performed in each hospital using a variety of
ifferent assays. However, residual blood samples were then
rought to a central laboratory for repeat measurement
sing a single high-performance assay. Biochemical analysis
f TnI was performed using the Accu TnI assay (Beckman
oulter). The interassay CV for TnI was 10% at 0.06 g/l.
otential decision points for TnI are 0.04 g/l (99th
ercentile value [9]) and 0.06 g/l (10% CV value [10]).
iven the implied imprecision of the assay below values
f 0.06 g/l, and in line with local practice and most
urrent thinking, we defined patients as being TnI
hen measured concentrations were 0.06 g/l and as
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November 20, 2007:2061–7 H-FABP Predicts Mortality in Acute Coronary SyndromenI when 0.06 g/l. This assay was selected for use
n the present study because it had a much better
erformance profile than most of the other assays that
ere in routine use (11).
tatistical analyses. Statistical analyses were performed
sing SPSS software (version 11.1, SPSS Inc., Chicago,
llinois). Data are presented as median (range) unless
therwise stated. Groups were compared using the chi-
quared test for categorical variables and analysis of variance
or continuous variables. Survival curves were generated by
eans of Kaplan-Meier estimates (univariable). Hazard
atios (HR) and 95% confidence intervals (CI) were also
alculated by constructing a univariable or multivariable
ogistic regression model. To explore the extent to which
-FABP produces prognostic information that is statisti-
ally independent, we performed logistic regression analyses
sing the nine variables from the GRACE (Global Registry
f Acute Coronary Events) prediction model (12): age,
revious history of heart failure, previous MI, heart rate on
dmission, systolic blood pressure on admission, ST-
egment depression on ECG, creatinine on admission,
levated cardiac markers, and inpatient percutaneous coro-
ary intervention plus highly sensitive C-reactive protein
hs-CRP). We used TnI as a continuous variable rather
han as the categoric variable described in the GRACE
aseline Factors According to H-FABP Quartile
Table 1 Baseline Factors According to H-FABP Quartile
H-FABP Q1: <6.4 g/l
(n  360)
H-FABP Q2: 6
(n 
Median age (yrs)* 65.0 (SD 12.5) 73.7 (
Gender (male) 61.7% (222) 55.5% (
Unstable angina 59.0% (105) 31.5% (
NSTEMI 24.8% (226) 27.0% (
STEMI/BBBMI 8.1% (29) 17.3% (
Heart failure* 1.7% (6) 8.2% (
Previous MI* 27.7% (100) 28.0% (
Prior PCI/CABG 17.8% (64) 13.7% (
Diabetes* 13.1% (47) 20.1% (
Smoking 29.2% (105) 23.4% (
Median heart rate
(beats/min)*
75 (SD 22.2) 80 (
Median SBP (mm Hg)* 142 (SD 28.0) 145 (
ST-segment depression
on ECG
15.8% (57) 19.5% (
Median creatinine
(mg/dl)*
1.01 (SD 0.24) 1.12 (
Troponin*†
Negative (0.06 g/l) 35.3% (127) 18.1% (
Q1 (0.07–0.47 g/l) 31.7% (114) 26.6% (
Q2 (0.48–2.39 g/l) 25.0% (90) 29.4% (
Q3 (2.40–12.68 g/l) 5.8% (21) 19.2% (
Q4 (12.68 g/l) 1.7% (6) 5.8% (
Inpatient PCI* 12.8% (46) 7.7% (
Inpatient CABG 3.6% (13) 2.5% (
Median hs-CRP‡ (g/l) 0.47 (SD 2.67) 0.75 (
Factor in GRACE risk model. †Troponin measured in central laboratory. ‡hs-CRP  highly sensit
BBBMI  bundle branch block myocardial infarction; CABG  coronary artery bypass surgery; E
cid-binding protein; MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocardial infa
TEMI  ST-segment elevation myocardial infarction.odel. For all tests, p values of0.05 were considered to be
tatistically significant. We also explored the extent to which
he selected H-FABP clinical cutoff value produced prog-
ostic information that was independent of standard clinical
redictors of risk as well as being complementary to the
linical cutoff values for TnI. The authors had full access to
he data and take responsibility for its integrity. All authors
ave read and agree to the manuscript as written.
esults
ohort description according to H-FABP quartile. The
MMACE-2 study identified and validated 2,499 patients
ith ACS. The 12-month mortality was identical for
atients included and excluded from this study. Further-
ore, a range of other descriptive factors were identical in
hose included and excluded from this study (data not
hown). The median age of patients included was 72.5 (SD
3) years; 885 were male (61%) and 563 were female (39%).
he majority of patients had non–ST-segment elevation
yocardial infarction (62.9%; n  911) compared with
T-segment elevation myocardial infarction (24.8%; n 
59) and unstable angina (12.3%; n  178). Table 1
rovides a summary of the cohort characteristics based on
uartiles for H-FABP.
4 g/l H-FABP Q3: 12.4–36.2 g/l
(n  362)
H-FABP Q4: >36.2 g/l
(n  362)
.7) 75.5 (SD 12.1) 74.2 (SD 13.2)
63.8% (231) 63.5% (230)
9.6% (17) 0% (0)
26.3% (240) 21.8% (199)
29.2% (105) 45.4% (163)
13.3% (48) 7.5% (27)
30.7% (111) 21.8% (79)
9.9% (36) 5.5% (20)
18.0% (65) 16.3% (59)
21.8% (79) 30.1% (109)
.5) 84 (SD 25.3) 80 (SD 22.5)
.9) 144 (SD 31.1) 138 (SD 29.7)
24.6% (89) 27.9% (101)
3) 1.70 (SD 1.28) 1.11 (SD 1.24)
6.4% (23) 0.3% (1)
19.3% (70) 6.4% (23)
21.3% (77) 8.0% (29)
30.7% (111) 27.9% (101)
21.5% (78) 55.5% (201)
4.1% (15) 5.0% (18)
3.3% (12) 1.1% (4)
7) 1.62 (SD 6.73) 4.28 (SD 6.91)
active protein, measured in central laboratory.
lectrocardiogram; GRACE  Global Registry of Acute Coronary Events; H-FABP  heart-type fatty.4–12.
364)
SD 11
202)
56)
246)
62)
30)
102)
50)
73)
85)
SD 24
SD 28
71)
SD 0.3
66)
97)
107)
70)
21)
28)
9)
SD 4.8
ive C-re
CG  erction; PCI  percutaneous coronary intervention; Q  quartile; SBP  systolic blood pressure;
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CI  confidence interval; hs-CRP  highly sensitive C-reactive protein; TnI  troponin I; other
abbreviations as in Table 1.
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H-FABP Predicts Mortality in Acute Coronary Syndrome November 20, 2007:2061–7ardiac markers. Heart-type fatty acid-binding protein
as measured in 1,448 samples and was observed to have a
ongaussian distribution with a median concentration of
2.2 g/l (range 1.5 to 944.4 g/l). Three hundred five
atients had H-FABP concentrations 5.8 g/l, and 1,143
ad concentrations 5.8 g/l. Troponin I had a nongaus-
ian distribution with a median concentration of 1.35 g/l
range 0.01 to 101 g/l). Two hundred seventeen patients
ad TnI concentrations 0.06 g/l and 1,210 patients had
oncentrations 0.06 g/l.
rognostic value of H-FABP. Figure 1 shows Kaplan-
eier all-cause mortality curves according to H-FABP
uartiles. Table 2 summarizes the findings of the univariable
nd multivariable analyses that we performed to assess the
agnitude of risk of 1-year all-cause mortality that was
ssociated with TnI and H-FABP quartiles. Next, we
ssessed the independence of each biomarker from other
linical risk factors in the GRACE model inclusive of
s-CRP. The adjusted HRs for H-FABP quartiles were:
1 1.0, Q2 2.32 (95% CI 1.25 to 4.30; p 0.007), Q3 3.17
95% CI 1.73 to 5.82; p  0.001), and Q4 4.88 (95% CI
.67 to 8.93; p  0.001). We then included TnI in the
ultivariable adjustment model to assess independence of
-FABP prognostic information from troponin. These
ensitivity analyses were performed in 3 separate ways,
ncluding: 1) elevated TnI (0.06 g/l) as an additional
ategoric variable: H-FABP Q1 HR 1.0, Q2 HR 2.44 (95%
I HR 1.29 to 4.60; p 0.006), Q3 HR 3.26 (95% CI 1.72
o 6.18; p  0.001), Q4 HR 4.77 (95% CI 2.50 to 9.12; p
0.001); 2) quartiles of elevated TnI relative to negative
roponin (0.06 g/l) as an additional categoric variable:
-FABP Q1 HR 1.0, Q2 HR 2.52 (95% CI 1.33 to 4.77;
Figure 1 Kaplan-Meier All-Cause Mortality
Curves According to H-FABP Quartiles
Kaplan-Meier all-cause mortality curves according to heart-type fatty acid-bind-
ing protein (H-FABP) quartiles (Q). After adjusting for all GRACE risk factors,
highly sensitive C-reactive protein (hs-CRP), and troponin I as a continuous vari-
able the following hazard ratios were observed: Q1 1.0, Q2 2.58 (95% confi-
dence interval [CI] 1.37 to 4.85; p  0.003), Q3 3.77 (95% CI 2.01 to 7.07; p
 0.001), and Q4 6.59 (95% CI 3.40 to 12.74; p  0.001).azard Ratios for 1-Year All-Cause Mortality
Table 2 Hazard Ratios for 1-Year All-Cause Mortality
Hazard Ratio (95% CI) p Value
(A) Univariable
Age (yrs) 1.08 (1.07–1.10) 0.001
History of heart failure 2.82 (1.88–4.22) 0.001
Previous MI 1.24 (0.94–1.64) 0.14 (NS)
Heart rate (per beat/min) 1.02 (1.01–1.02) 0.001
SBP (per mm Hg) 0.99 (0.99–0.99) 0.001
ST-segment depression on ECG 1.81 (1.36–2.41) 0.001
Creatinine (per mg/dl) 1.82 (1.47–2.26) 0.001
Inpatient PCI 0.10 (0.03–0.33) 0.001
hs-CRP (per g/l) 1.12 (1.09–1.14) 0.001
TnI negative (0.06 g/l) 1.00
Q1 (0.07–0.47 g/l) 2.21 (1.32–3.69) 0.003
Q2 (0.48–2.39 g/l) 2.08 (1.24–3.49) 0.005
Q3 (2.40–12.68 g/l) 2.53 (1.53–4.21) 0.001
Q4 (12.68 g/l) 2.74 (1.65–4.54) 0.001
H-FABP
Q1 (6.38 g/l) 1.00
Q2 (6.38–12.39 g/l) 4.45 (2.47–8.00) 0.001
Q3 (12.39–36.2 g/l) 8.78 (4.99–15.46) 0.001
Q4 (36.2 g/l) 11.69 (6.67–20.49) 0.001
(B) TnI multivariable
Age (per yr) 1.07 (1.06–1.09) 0.001
History of heart failure 1.55 (0.96–250) 0.073 (NS)
Previous MI 1.11 (0.79–1.55) 0.55 (NS)
Heart rate (per beat/min) 1.007 (1.001–1.013) 0.028
SBP (per mm Hg) 0.995 (0.990–1.000) 0.039
ST-segment depression on ECG 1.37 (0.98–1.93) 0.069
Creatinine (mg/dl) 1.36 (1.12–1.66) 0.002
Inpatient PCI 0.37 (0.11–1.23) 0.11 (NS)
hs-CRP (per g/l) 1.08 (1.06–1.11) 0.001
TnI
Negative (0.06 g/l) 1.00
Q1 (0.07–0.47 g/l) 1.56 (0.88–2.76) 0.13 (NS)
Q2 (0.48–2.39 g/l) 1.66 (0.94–2.95) 0.081 (NS)
Q3 (2.40–12.68 g/l) 1.91 (1.09–3.37) 0.025
Q4 (12.68 g/l) 2.38 (1.35–4.19) 0.003
(C) H-FABP multivariable
Age (per yr) 1.06 (1.05–1.08) 0.001
History of heart failure 1.45 (0.90–2.33) 0.12 (NS)
Previous MI 1.15 (0.82–1.60) 0.43 (NS)
Heart rate (per beat/min) 1.008 (1.002–1.014) 0.013
SBP (per mm Hg) 0.995 (0.990–1.000) 0.045
ST-segment depression on ECG 1.36 (0.97–1.91) 0.076 (NS)
Creatinine (per mg/dl) 1.20 (0.99–1.44) 0.061 (NS)
Inpatient PCI 0.40 (0.12–1.33) 0.14 (NS)
hs-CRP (per g/l) 1.08 (1.05–1.10) 0.001
H-FABP
Q1 (6.38 g/l) 1.0
Q2 (6.38–12.39 g/l) 2.32 (1.25–4.30) 0.007
Q3 (12.39–36.2 g/l) 3.17 (1.73–5.82) 0.001
Q4 (36.2 g/l) 4.88 (2.67–8.93) 0.001
A) Unadjusted for other factors; (B) TnI quartiles adjusted for the GRACE risk factors plus hs-CRP;
C) H-FABP quartiles adjusted for the GRACE risk factors plus hs-CRP with TnI as a continuous
ariable.
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4 HR 5.54 (95% CI 2.69 to 11.38; p 0.001); and 3) TnI
s an additional continuous variable: H-FABP Q1 HR 1.0,
2 HR 2.58 (95% CI 1.37 to 4.85; p  0.003), Q3 HR
.77 (95% CI 2.01 to 7.07; p  0.001), Q4 HR 6.59 (95%
I 3.40 to 12.74; p  0.001). Table 3 extends this analysis
o assess the magnitude of risk associated with H-FABP
uartiles once the cohort had been stratified by TnI quartile.
n all 4 TnI quartiles H-FABP provided concentration-
elated additional information regarding clinical risk. As-
essment of TnI quartile 4 was made more difficult by the
bsence of any deaths in the H-FABP reference group
Q1), although this in itself provides strong support for the
omplementary information carried by a low concentration
f H-FABP.
Next we described the mortality and the adjusted multi-
ariable prognostic value of the H-FABP clinical cutoff
cross a range of acute coronary syndrome subtypes defined
y ECG in conjunction with troponin (Table 4). This
emonstrated the additive value of H-FABP, particularly
or ACS subtypes such as unstable angina, traditionally
nI and H-FABP Concentration Quartiles
Table 3 TnI and H-FABP Concentration Quartiles
TnI Negative
(<0.06 g/l)
TnI Q1
(0.07–0.47 
(A) H-FABP mortality
Q1 (6.38 g/l) 3.1% (4) 5.3% (6
Q2 (6.38–12.39 g/l) 18.2% (12) 17.5% (1
Q3 (12.39–36.2 g/l) 30.4% (7) 41.4% (2
Q4 (36.2 g/l) 0% (0) 47.8% (1
All quartiles 10.6% (23) 20.7% (6
(B) H-FABP adjusted HR (95% CI)
Q1 (6.38 g/l) 1.00 1.00
Q2 (6.38–12.39 g/l) 6.50 (1.53–27.71)
p  0.011
2.09 (0.72–6
p  0.18 (N
Q3 (12.39–36.2 g/l) 5.79 (1.08–31.12)
p  0.041
4.93 (1.73–1
p  0.003
Q4 (36.2 g/l) —* 8.26 (2.19–3
p  0.002
A) All-cause mortality and (B) adjusted hazard ratio modeled using the significant GRACE risk facto
H-FABP Q4 and TnI Negative), it was not possible to calculate the hazard ratios (HRs).
Abbreviations as in Tables 1 and 2.
ll-Cause Mortality According to H-FABP DiagnosticCutoff” With Hazard Ratio Adjusted Using GRACEisk Factors Plus hs-CRP With TnI as an Additi nalon inuous Vari ble
Table 4
All-Cause Mortality According to H-FABP Diagnostic
“Cutoff” With Hazard Ratio Adjusted Using GRACE
Risk Factors Plus hs-CRP With TnI as an Additional
Continuous Variable
Unstable Angina NSTEMI STEMI/BBBMI
H-FABP (5.8g/l) 2.1% (2) 4.8% (9) 0% (0)
H-FABP (5.8g/l) 22.9% (19) 26.1% (189) 23.0% (77)
Adjusted HR 11.35 3.11 —*
95% CI 2.00–64.34 1.45–6.70 —*
p Value 0.006 0.004 —*
nstable angina is defined as TnI 0.06 g/l and no ST-segment elevation or new BBB on
dmission ECG. NSTEMI is defined as TnI0.06 g/l and no ST-segment elevation or new BBB on
CG. STEMI/BBBMI is defined as ST-segment elevation or new bundle branch block on admission
CG with supporting clinical and/or biomarker data). *Because there were no deaths in the(
eference group (H-FABP 5.8 g/l) it was not possible to calculate the HR.
Abbreviations as in Tables 1, 2, and 3.onsidered to be associated with a low long-term risk. The
rude all-cause 1-year mortality for unstable angina patients
ith H-FABP 5.8 g/l was 2.1% compared with 22.9%
or patients above this cutoff. The adjusted all-cause mor-
ality HR in this group was 11.35 (95% CI 2.00 to 64.34;
 0.006). Figure 2A depicts Kaplan-Meier mortality
urves for patients in each of the 4 subgroups based on the
esults of TnI and H-FABP measurement, i.e., TnI/H-
ABP, TnI/H-FABP, TnI/H-FABP, and
nI/H-FABP. Figure 2B depicts the corresponding
ox regression curves after adjustment for other covariables.
s shown, measurement of H-FABP discriminated be-
ween high- and low-risk patients with ACS, both before
nd after adjustment for other covariables. The occurrence
f a negative test result for both TnI and H-FABP was
ssociated with zero mortality (no deaths) before 6 months.
iscussion
he present data indicate that measurement of H-FABP 12
o 24 h after the onset of symptoms provides information
hat is additive to that provided by the GRACE risk factors,
ncluding as well TnI and hs-CRP as continuous variables.
his reinforces the conclusions of a recent investigation
egarding measurement of H-FABP in conjunction with
roponin T within 6 h of the onset of chest pain (13) and a
ore recent report of samples taken later after a mean of
1 h (6). These studies used different diagnostic cutoffs of
.8 and 8 g/l, respectively, owing to the performance of the
assays. Our decision to use a value of 5.8 g/l as a basis for
iscriminating between patients was based on an assessment
f the 99th percentile for healthy caucasian Europeans. It is
pparent that H-FABP is able to distinguish between low-
nd high-risk patients across a wide range of TnI values
TnI Q2
(0.48–2.39 g/l)
TnI Q3
(2.40–12.68 g/l)
TnI Q4
(>12.68 g/l)
4.4% (4) 0% (0) 0% (0)
18.7% (20) 11.4% (8) 9.5% (2)
32.5% (25) 24.3% (27) 15.4% (12)
37.9% (11) 34.6% (35) 30.3% (61)
19.8% (60) 23.1% (70) 24.5% (75)
1.00 1.00 1.00
2.99 (0.94–9.57)
p  0.065 (NS)
—* —*
4.30 (1.31–14.17)
p  0.016
—* —*
6.03 (1.58–23.01)
p  0.009
—* —*
hs-CRP and TnI as an additional continuous variable. *Because there were no deaths in the groupg/l)
)
7)
9)
1)
3)
.08)
S)
4.03)
1.09)
rs plusTable 3) and at all parts of the ACS spectrum (Table 4).
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H-FABP Predicts Mortality in Acute Coronary Syndrome November 20, 2007:2061–7Despite the use of H-FABP in earlier studies, it has not
ained widespread use. This is likely owing to the relatively
oor analytic sensitivity of early assays, the relatively small
linical studies, and the absence of long-term clinical out-
ome data. We have shown that H-FABP is useful as a
arker in conjunction with TnI. Heart-type fatty acid-
inding protein not only offers independent prognostic
nformation but also, more importantly, confirms the find-
ng of O’Donoghue et al. (6) that H-FABP identifies
igh-risk patients who are considered to be troponin neg-
Figure 2 All-Cause Mortality by TnI
and H-FABP Clinical Cutoff Values
(A) Kaplan-Meier mortality curves for patients with either TnI  0.06 g/l
(unstable angina) or TnI 0.06 g/l (MI inclusive of STEMI/BBBMI) according
to the H-FABP cutoff value of 5.8 g/l. One-year univariable hazard ratios for
each group relative to TnI/H-FABP patients are: TnI/H-FABP 2.38 (95%
CI 0.48 to 11.65; p  0.29), TnI/H-FABP 4.93 (95% CI 1.09 to 22.30; p 
0.038), and TnI/H-FABP 7.11 (1.71 to 29.64; p  0.007). (B) Cox regres-
sion mortality curves for patients with either TnI  0.06 g/l (unstable angina)
or TnI 0.06 g/l (MI inclusive of STEMI/BBBMI) according to the H-FABP cut-
off value of 5.8 g/l. One-year multivariable (GRACE risk factors plus hs-CRP)
hazard ratios for each group relative to TnI/H-FABP patients are: TnI/H-
FABP 2.31 (95% CI 0.49 to 10.90; p  0.29), TnI/H-FABP 5.21 (95% CI
1.21 to 22.47; p  0.027), and TnI/H-FABP 7.41 (95% CI 1.83 to 30.00;
p  0.005). BBBMI  bundle branch block myocardial infarction; MI  myocar-
dial infarction; STEMI  ST-segment elevation myocardial infarction; TnI  tro-
ponin I; other abbreviations as in Figure 1.tive. The importance of the present study is that it was bone on a population-based cohort of patients diagnosed
ith ACS (mostly MI) in whom an important factor
nvolved in selection was the presence of sufficient redun-
ant serum after routine analysis. The patients were of an
ge range which is older than seen in clinical trials and
onsequently also had a higher mortality. Both of these
actors enhance the statistical power of our assessment of
-FABP. Our samples were taken at 12 to 24 h after
ymptom onset, whereas the O’Donoghue study used sub-
ects from the OPUS (Orbofiban in Patients with Unstable
oronary Syndromes)–TIMI-16 study who were younger
han the present population, and their samples were taken even
ater, at a mean time of 41 h after the onset of symptoms.
For patients who present with symptoms and ECG
hanges of ischemic heart disease and who are diagnosed
linically as having ACS, detectable troponin is considered
o be a marker of myocyte necrosis. However, the cutoff
alue used to distinguish between probable normality and
ossible abnormality has been subject to limited assay
recision and consequently remains poorly defined. Some
ave recommended use of the value at which the assay has
CV (a measure of precision) of 10% (10), whereas others
ave recommended use of the 99th percentile (3 standard
eviations above the mean) based on a population of normal
ndividuals. For the TnI assay that we have used within the
ontext of a central laboratory, the 99th percentile is reported
o be 0.04 g/l (9). Despite being one of the most precise
ssays available at the time, the CV at 0.04 g/l remained high
t 14%. The implications of this would be that patients may be
ncorrectly stratified and treated. Fortunately, more precise
roponin assays have now started to emerge. Nevertheless,
able 3 indicates that across the full range of troponin
oncentrations, H-FABP measurement provides prognostic
nformation that is independent of other clinical risk factors
nd additive to the information denoted by troponin.
In contrast with other prognostic markers, such as hs-
RP and B-type natriuretic peptide, H-FABP provides
irect evidence not only of acute myocyte necrosis, but also
f myocardial ischemia (14,15). Meng et al. (14) demon-
trated that in rats the H-FABP concentration in peripheral
lood was 4 the baseline after just 15 min induced
yocardial ischemia. Also, in human autopsy cases it was
ossible to demonstrate depletion of H-FABP in the
yocardium of individuals dying suddenly after the onset of
hest pain. These changes were present despite the absence
f myocyte necrosis on electron microscopy. This caused
hose investigators to conclude that H-FABP is both a
ensitive and an early marker of myocardial ischemia. Such
conclusion is intuitive, given that H-FABP is confined to
he cytoplasm and because of its small molecular size,
ecause both of these features permit early leakage through
he porous membranes of ischemic myocardial cells.
tudy limitations. Limitations of the present investigation
nclude the fact that we studied a high-risk cohort of
atients with confirmed ACS and that we studied a single
lood sample taken at 12 to 24 h after symptom onset.
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November 20, 2007:2061–7 H-FABP Predicts Mortality in Acute Coronary Syndromeowever, further studies are currently being conducted
sing multiple measurements in unselected patients present-
ng to the emergency room with undifferentiated chest pain.
ther limitations in our conclusions may relate to the
ethod of risk adjustment that we used. We opted to
nclude factors that form part of the well validated
RACE risk model to permit the reasons for factor
election to be fully transparent. However, because this
odel uses troponin elevation as a categoric variable, we
lso assessed the effects of using troponin as a continuous
ariable and adjusted as well for baseline hs-CRP mea-
urement. Another weakness, although also possibly a
trength, of this study was the low rate of in-hospital
ercutaneous coronary intervention (13%). This reflects
rovincial United Kingdom practice in 2003 and may
nadvertently have permitted a clearer assessment of the
atural history of H-FABP changes in the context of ACS.
he fact that 87.7% of the patients studied had an elevated
nI (MI) and just 12.3% had troponin-negative unstable
ngina should also be noted when interpreting these data.
onclusions
ur results indicate that raised concentrations of H-FABP
re strongly predictive of mortality after ACS. Furthermore,
-FABP identifies patients who are high risk across the full
ange of TnI concentrations. This might be explained by a
ossible role for H-FABP in denoting the presence of
yocardial ischemia either in the presence or the absence of
yocardial necrosis denoted by detecting raised levels of
nI. The occurrence of a negative test result for both TnI
nd H-FABP was associated with zero mortality (no
eaths) before 6 months. This appears to represent a
articularly worthwhile clinical outcome, especially be-
ause it was observed in patients admitted into hospital
or suspected ACS. Such an observation would give
onfidence to physicians assessing unselected suspected
CS patients in the emergency room, particularly if
eproduced using much earlier blood samples. In this
egard, we believe that measurement of H-FABP may
ave a great deal to offer in routine clinical care and
herefore deserves further research.
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